Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen
Related Research units
Abstract
Catechol O‑methyltransferase (COMT) inhibitors have been established in the treatment of Parkinson's disease for more than 20 years. They are considered the medication of choice for treating motor fluctuations. The available COMT inhibitors, entacapone, opicapone and tolcapone, differ pharmacokinetically in terms of their half-lives with implications for the dose frequency, in their indication requirements and in their spectrum of side effects, including diarrhea and yellow discoloration of urine. Many patients with motor fluctuations are currently not treated with COMT inhibitors and are, therefore, unlikely to receive individually optimized drug treatment. This manuscript summarizes the results of a working group including several Parkinson's disease experts, in which the value of COMT inhibitors was critically discussed.
Bibliographical data
Translated title of the contribution | Relevance of COMT inhibitors in the treatment of motor fluctuations |
---|---|
Original language | German |
ISSN | 0028-2804 |
DOIs | |
Publication status | Published - 10.2022 |
Comment Deanary
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
PubMed | 35044481 |
---|